0
Obstructive Lung Diseases |

Physician-Ordered Aerosol Therapy vs. Respiratory Therapist-Driven Aerosol Protocol: The Effect on Resource Utilization FREE TO VIEW

Avyakta Kallam*, MD; Kathy Meyerink, RRT; Ariel Modrykamie, MD
Author and Funding Information

Creighton University, Omaha, NE


Chest. 2012;142(4_MeetingAbstracts):656A. doi:10.1378/chest.1380620
Text Size: A A A
Published online

Abstract

SESSION TYPE: COPD Posters II

PRESENTED ON: Wednesday, October 24, 2012 at 01:30 PM - 02:30 PM

PURPOSE: The utilization of respiratory therapist-driven protocols is associated with improvements in resource utilization. Based on this, we started a quality improvement (QI) project to transition the delivery of respiratory care services from physician-ordered treatments to therapist-driven protocols. During the first phase of our QI project, we compared the frequency of bronchodilator administration, and its associated costs, between a physician-ordered bronchodilator strategy and a therapist-driven bronchodilator protocol strategy

METHODS: This was a retrospective analysis of data obtained during the initial phase of a QI project. Over a period of two weeks, respiratory therapists administered physician-ordered bronchodilator treatments and, simultaneously, they assessed patients’ severity levels and frequency of bronchodilator treatments that they would have administered if the protocol would have been followed. Forty-eight patients were ordered bronchodilator treatments, which resulted in eighty-eight assessments.

RESULTS: The utilization of a respiratory therapist-driven protocol would have resulted in 47.7% of all bronchodilator orders administered ‘every six hours, as needed’, and 30.6% of these orders administered ‘every eight hours’. Conversely, physician-ordered treatments were prescribed ‘every 4 hours’ in 63.6% of the cases. Total bronchodilator therapy cost in the physician-ordered group was $94,218.19, whereas it would have been $46,948.40 in the therapist-driven one. Per patient costs were $1070 (±262) in the physician-ordered, and it would have been $978 (±649) in the therapist-driven bronchodilator protocol group (p = 0.24).

CONCLUSIONS: The applications of a therapist-driven bronchodilator protocol can reduce the frequency of bronchodilator treatments compared with a physician-ordered treatment strategy. Costs of bronchodilator treatments, mostly the ones associated with respiratory therapist charges, may be reduced when therapist-driven protocols are utilized.

CLINICAL IMPLICATIONS: Utilization of therapist-driven bronchodilator protocols may reduce health-care costs.

DISCLOSURE: The following authors have nothing to disclose: Avyakta Kallam, Kathy Meyerink, Ariel Modrykamie

No Product/Research Disclosure Information

Creighton University, Omaha, NE

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
In vitro evaluation of the DP-4M PennCentury™ insufflator. Eur J Pharm Biopharm Published online Jun 30, 2014.;
Drug delivery to paranasal sinuses using pulsating aerosols. J Aerosol Med Pulm Drug Deliv 2014;27(4):255-63.
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543